ACM
SUPN icon

AlphaCrest Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

AlphaCrest Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-73,504
Closed -$2.49M – 1008
2022
Q3 		$2.49M Buy
73,504
+23,962
+48% +$780K 0.15% 152
2022
Q2 		$1.43M Buy
+49,542
New +$1.42M 0.07% 497
2022
Q1 		– Sell
-32,459
Closed -$947K – 1404
2021
Q4 		$947K Buy
32,459
+2,229
+7% +$67.6K 0.04% 821
2021
Q3 		$806K Buy
30,230
+6,115
+25% +$164K 0.04% 705
2021
Q2 		$743K Sell
24,115
-1,139
-5% -$34.9K 0.03% 793
2021
Q1 		$661K Buy
25,254
+6,729
+36% +$188K 0.04% 669
2020
Q4 		$466K Sell
18,525
-8,396
-31% -$181K 0.04% 686
2020
Q3 		$561K Buy
+26,921
New +$611K 0.06% 527
2020
Q2 		– Sell
-37,650
Closed -$677K – 1108
2020
Q1 		$677K Buy
37,650
+26,894
+250% +$565K 0.08% 437
2019
Q4 		$255K Sell
10,756
-19,944
-65% -$484K 0.02% 1141
2019
Q3 		$844K Buy
30,700
+16,800
+121% +$498K 0.05% 661
2019
Q2 		$460K Sell
13,900
-9,500
-41% -$325K 0.04% 724
2019
Q1 		$820K Buy
23,400
+8,900
+61% +$331K 0.12% 263
2018
Q4 		$482K Buy
+14,500
New +$624K 0.14% 256

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

AlphaCrest Capital Management's SUPN Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of Supernus Pharmaceuticals (SUPN) in Q4 2022, closing a stake of 73,504 shares — an estimated $2.49M sold.

AlphaCrest Capital Management first reported a position in SUPN in Q4 2018 and held it in 14 quarters. The position peaked at $2.49M in Q3 2022. 263 funds tracked by Wall St. Rank hold SUPN as of Q4 2022.

  • AlphaCrest Capital Management reported no remaining Supernus Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • AlphaCrest Capital Management sold 73,504 Supernus Pharmaceuticals shares in Q4 2022, an estimated $2.49M.
  • AlphaCrest Capital Management first reported a position in Supernus Pharmaceuticals in Q4 2018 and held it in 14 quarters.
  • AlphaCrest Capital Management's Supernus Pharmaceuticals position peaked at $2.49M in Q3 2022.
  • 263 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.